SciClone Pharmaceuticals Company Profile (NASDAQ:SCLN)

About SciClone Pharmaceuticals

SciClone Pharmaceuticals logoSciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company's product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company's lead product ZADAXIN (thymalfasin) is approved in approximately 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, the Company markets approximately seven partnered and in-licensed products in China. The Company's development portfolio includes Angiomax, Neucardin, Loramyc, Cleviprex, RapidFilm, VIBATIV and SGX942. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: SCLN
  • CUSIP: 80862K10
Key Metrics:
  • Previous Close: $9.75
  • 50 Day Moving Average: $10.12
  • 200 Day Moving Average: $10.14
  • 52-Week Range: $7.51 - $15.02
  • Trailing P/E Ratio: 13.79
  • Foreward P/E Ratio: 15.08
  • P/E Growth: 0.00
  • Market Cap: $492.66M
  • Outstanding Shares: 51,053,000
  • Beta: 1.66
Profitability:
  • Net Margins: 23.20%
  • Return on Equity: 22.10%
  • Return on Assets: 19.47%
Debt:
  • Current Ratio: 7.49%
  • Quick Ratio: 6.93%
Additional Links:
Companies Related to SciClone Pharmaceuticals:

Analyst Ratings

Consensus Ratings for SciClone Pharmaceuticals (NASDAQ:SCLN) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $14.00 (45.08% upside)

Analysts' Ratings History for SciClone Pharmaceuticals (NASDAQ:SCLN)
Show:
DateFirmActionRatingPrice TargetDetails
1/17/2017Maxim GroupSet Price TargetBuy$14.00View Rating Details
7/9/2015BWS FinancialDowngradeHold -> SellView Rating Details
6/29/2015MLV & Co.Initiated CoverageBuyView Rating Details
(Data available from 2/25/2015 forward)

Earnings

Earnings History for SciClone Pharmaceuticals (NASDAQ:SCLN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/8/2017        
5/10/2016Q116$0.19$33.60 million$36.50 millionViewListenView Earnings Details
3/10/2016Q415$0.30$41.10 million$42.90 millionViewListenView Earnings Details
11/9/2015Q315$0.12$0.26$40.61 million$42.90 millionViewN/AView Earnings Details
8/10/2015Q215$0.12$0.26$37.27 million$37.90 millionViewListenView Earnings Details
5/11/2015Q414$0.03$0.17$34.00 million$33.60 millionViewListenView Earnings Details
3/11/2015Q4$0.15$0.29$38.93 million$41.43 millionViewN/AView Earnings Details
11/10/2014Q314$0.12$0.17$34.90 million$34.30 millionViewN/AView Earnings Details
8/11/2014Q214$0.10$0.20$33.40 million$32.50 millionViewListenView Earnings Details
5/12/2014Q114$0.08$0.10$32.20 million$26.60 millionViewListenView Earnings Details
3/12/2014Q314$0.15$0.08$38.30 million$32.70 millionViewListenView Earnings Details
11/12/2013Q114$0.15$0.18$39.70 million$35.20 millionViewListenView Earnings Details
8/7/2013Q2 2013$0.11$0.09$33.30 million$29.81 millionViewListenView Earnings Details
4/1/2013Q4 2012$0.12$0.04$35.30 million$33.10 millionViewListenView Earnings Details
11/9/2012Q312$0.21$0.20$43.09 million$40.70 millionViewN/AView Earnings Details
8/8/2012$0.18$0.20ViewN/AView Earnings Details
5/9/2012$0.11$0.15ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for SciClone Pharmaceuticals (NASDAQ:SCLN)
Current Year EPS Consensus Estimate: $0.33 EPS
Next Year EPS Consensus Estimate: $0.64 EPS

Dividends

Dividend History for SciClone Pharmaceuticals (NASDAQ:SCLN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for SciClone Pharmaceuticals (NASDAQ:SCLN)
Insider Ownership Percentage: 7.63%
Institutional Ownership Percentage: 76.93%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/23/2017Friedhelm BlobelCEOSell39,177$9.83$385,109.91View SEC Filing  
1/25/2017Friedhelm BlobelCEOSell8,868$10.54$93,468.72View SEC Filing  
1/24/2017Friedhelm BlobelCEOSell61,132$10.44$638,218.08View SEC Filing  
1/5/2017Friedhelm BlobelCEOSell9,600$11.02$105,792.00View SEC Filing  
12/22/2016Friedhelm BlobelCEOSell70,000$10.55$738,500.00View SEC Filing  
11/22/2016Friedhelm BlobelCEOSell70,000$10.22$715,400.00View SEC Filing  
11/14/2016Friedhelm BlobelCEOSell30,000$10.27$308,100.00View SEC Filing  
10/27/2016Friedhelm BlobelCEOSell40,000$9.30$372,000.00View SEC Filing  
10/26/2016Wilson Wai-Shun CheungCFOSell149,962$10.00$1,499,620.00View SEC Filing  
10/17/2016Wilson Wai-Shun CheungCFOSell1,475$10.00$14,750.00View SEC Filing  
8/30/2016Nancy T ChangDirectorSell25,040$10.30$257,912.00View SEC Filing  
8/29/2016Wilson Wai-Shun CheungCFOSell1,872$10.35$19,375.20View SEC Filing  
8/17/2016Friedhelm BlobelCEOSell501,875$10.00$5,018,750.00View SEC Filing  
8/16/2016Wilson Wai-Shun CheungCFOSell7,802$10.62$82,857.24View SEC Filing  
3/28/2016Friedhelm BlobelCEOSell10,000$9.29$92,900.00View SEC Filing  
3/18/2016Friedhelm BlobelCEOSell10,000$9.09$90,900.00View SEC Filing  
3/7/2016Friedhelm BlobelCEOSell20,000$10.01$200,200.00View SEC Filing  
2/26/2016Friedhelm BlobelCEOSell10,000$9.98$99,800.00View SEC Filing  
1/4/2016Friedhelm BlobelCEOSell200$9.01$1,802.00View SEC Filing  
12/28/2015Friedhelm BlobelCEOSell10,000$9.17$91,700.00View SEC Filing  
12/17/2015Friedhelm BlobelCEOSell9,400$9.00$84,600.00View SEC Filing  
12/11/2015Friedhelm BlobelCEOSell600$9.00$5,400.00View SEC Filing  
12/4/2015Friedhelm BlobelCEOSell10,000$9.22$92,200.00View SEC Filing  
12/3/2015Lan XieCFOSell14,166$9.50$134,577.00View SEC Filing  
11/27/2015Friedhelm BlobelCEOSell10,000$9.24$92,400.00View SEC Filing  
11/10/2015Wilson Wai-Shun CheungCFOSell7,803$9.51$74,206.53View SEC Filing  
7/24/2015Friedhelm BlobelCEOSell10,000$9.68$96,800.00View SEC Filing  
7/17/2015Friedhelm BlobelCEOSell10,000$9.72$97,200.00View SEC Filing  
7/10/2015Friedhelm BlobelCEOSell10,000$9.21$92,100.00View SEC Filing  
7/6/2015Friedhelm BlobelCEOSell20,000$10.80$216,000.00View SEC Filing  
6/26/2015Friedhelm BlobelCEOSell10,000$9.29$92,900.00View SEC Filing  
6/19/2015Friedhelm BlobelCEOSell10,000$9.42$94,200.00View SEC Filing  
6/12/2015Chuncai MengVPSell3,007$9.23$27,754.61View SEC Filing  
6/12/2015Friedhelm BlobelCEOSell10,000$9.13$91,300.00View SEC Filing  
6/8/2015Hong ZhaoCEOSell10,000$9.23$92,300.00View SEC Filing  
6/5/2015Friedhelm BlobelCEOSell10,000$9.07$90,700.00View SEC Filing  
6/1/2015Richard J HawkinsDirectorSell4,570$9.27$42,363.90View SEC Filing  
5/29/2015Friedhelm BlobelCEOSell10,000$9.38$93,800.00View SEC Filing  
5/29/2015Richard J HawkinsDirectorSell10,430$9.32$97,207.60View SEC Filing  
5/26/2015Richard J HawkinsDirectorSell11,982$9.44$113,110.08View SEC Filing  
5/22/2015Friedhelm BlobelCEOSell10,000$9.40$94,000.00View SEC Filing  
5/18/2015Chuncai MengVPSell23,660$9.56$226,189.60View SEC Filing  
5/15/2015Lan XieCFOSell26,668$9.20$245,345.60View SEC Filing  
4/24/2015Friedhelm BlobelCEOSell10,000$9.07$90,700.00View SEC Filing  
4/10/2015Friedhelm BlobelCEOSell10,000$9.10$91,000.00View SEC Filing  
3/12/2015Wilson Wai-Shun CheungCFOSell7,803$9.07$70,773.21View SEC Filing  
12/11/2014Richard J HawkinsDirectorSell15,591$8.80$137,200.80View SEC Filing  
9/2/2014Lan XieCFOSell36,468$6.97$254,181.96View SEC Filing  
8/15/2014Nancy T ChangDirectorBuy25,040$6.00$150,240.00View SEC Filing  
5/16/2014Hong ZhaoCEOSell12,500$4.75$59,375.00View SEC Filing  
8/22/2013Min YinVPSell10,938$5.50$60,159.00View SEC Filing  
8/20/2013Min YinVPSell12,500$5.50$68,750.00View SEC Filing  
2/28/2013Friedhelm BlobelCEOBuy3,000$3.86$11,580.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for SciClone Pharmaceuticals (NASDAQ:SCLN)
DateHeadline
News IconInvesting Focus: Indicators in View on Shares of SciClone Pharmaceuticals Inc (SCLN) - Davidson Register (NASDAQ:SCLN)
davidsonregister.com - February 24 at 9:38 PM
marketexclusive.com logoInsider Trading Activity SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) – CEO Sold 39177 shares of Stock - Market Exclusive (NASDAQ:SCLN)
marketexclusive.com - February 24 at 9:38 PM
News IconChecking Indicator Levels for SciClone Pharmaceuticals Inc (SCLN) - Rives Journal (NASDAQ:SCLN)
rivesjournal.com - February 23 at 8:07 AM
News IconStock Check: Reviewing the Numbers for SciClone Pharmaceuticals Inc (SCLN) - Davidson Register (NASDAQ:SCLN)
davidsonregister.com - February 21 at 5:09 PM
finance.yahoo.com logoSciClone Pharmaceuticals To Report Fourth Quarter And Full Year 2016 Financial Results On March 6, 2017 (NASDAQ:SCLN)
finance.yahoo.com - February 21 at 5:09 PM
4-traders.com logoSciClone Pharmaceuticals : Healthcare Stocks Under Scanner -- Aerie Pharma, GW Pharma, Retrophin, and SciClone Pharma (NASDAQ:SCLN)
www.4-traders.com - February 11 at 12:29 AM
finance.yahoo.com logoSciClone To Present At BIO CEO & Investor Conference On February 13, 2017 (NASDAQ:SCLN)
finance.yahoo.com - February 2 at 12:38 AM
capitalcube.com logoSciClone Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SCLN-US : January 30, 2017 (NASDAQ:SCLN)
www.capitalcube.com - January 30 at 9:09 PM
News IconLevels in View on Shares of SciClone Pharmaceuticals, Inc ... - The Tribune (NASDAQ:SCLN)
lakecitytribune.com - January 26 at 4:43 AM
realistinvestor.com logoQuarterly Deferred Tax Assets Of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) At $0.094 Millions - RealistInvestor.com (NASDAQ:SCLN)
www.realistinvestor.com - January 15 at 12:46 AM
capitalcube.com logoSciClone Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SCLN-US : January 11, 2017 (NASDAQ:SCLN)
www.capitalcube.com - January 11 at 10:34 PM
marketexclusive.com logoSciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Files An 8-K Departure of Directors or Certain Officers; Election of ... - Market Exclusive (NASDAQ:SCLN)
marketexclusive.com - January 9 at 12:35 AM
biz.yahoo.com logoSCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:SCLN)
biz.yahoo.com - January 6 at 9:50 PM
realistinvestor.com logoQuarterly Accounts Payable Change Of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) At $-2.47 Millions - RealistInvestor.com (NASDAQ:SCLN)
www.realistinvestor.com - December 31 at 7:32 PM
marketexclusive.com logoInsider Trading Activity SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) – CEO Sold 70,000 shares of Stock (NASDAQ:SCLN)
marketexclusive.com - December 24 at 7:08 PM
marketexclusive.com logoInsider Trading Activity SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) – CEO Sold 70000 shares of Stock - Market Exclusive (NASDAQ:SCLN)
marketexclusive.com - December 24 at 12:54 AM
News IconInsider Heat: The Insider and President & CEO of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN), Friedhelm Blobel ... - Thorold News (NASDAQ:SCLN)
www.whatsonthorold.com - December 22 at 8:07 PM
News IconTechnical Roundup on Shares of SciClone Pharmaceuticals Inc. (SCLN) - StockTalk Daily (NASDAQ:SCLN)
stocktalkdaily.com - December 21 at 10:41 PM
News IconCompany Shares in Review: SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) - OIB News (NASDAQ:SCLN)
oibnews.com - December 21 at 10:41 PM
News IconCompany in Focus: SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) - Liberty News (NASDAQ:SCLN)
libertynewsrecord.com - December 20 at 2:33 PM
capitalcube.com logoSciClone Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SCLN) : December 19, 2016 (NASDAQ:SCLN)
www.capitalcube.com - December 20 at 2:33 PM
realistinvestor.com logoSciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Quarterly Deferred Tax Assets At $0.094 Millions - RealistInvestor.com (NASDAQ:SCLN)
www.realistinvestor.com - December 18 at 1:21 AM
News IconCompany Focus on Shares of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) - Business Daily Leader (NASDAQ:SCLN)
businessdailyleader.com - December 18 at 1:21 AM
capitalcube.com logoSciClone Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SCLN-US : December 16, 2016 (NASDAQ:SCLN)
www.capitalcube.com - December 16 at 11:19 PM
News IconInvestor Corner: Checking the Numbers on SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) - OIB News (NASDAQ:SCLN)
oibnews.com - December 16 at 3:17 AM
News IconInvestor Radar: Taking a Closer Look at SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) - The Business Journal (NASDAQ:SCLN)
belmontbusinessjournal.com - December 13 at 8:08 PM
News IconInvestor Hub: Looking at Shares of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) - OIB News (NASDAQ:SCLN)
oibnews.com - December 13 at 8:08 PM
insidermonkey.com logoHedge Funds Are Buying SciClone Pharmaceuticals, Inc. (SCLN) - Insider Monkey (blog) (NASDAQ:SCLN)
www.insidermonkey.com - December 13 at 8:08 PM
News IconHedge Funds Are Buying SciClone Pharmaceuticals, Inc. (SCLN) (NASDAQ:SCLN)
feedproxy.google.com - December 13 at 4:28 PM
News IconROIC Watch for SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) - Liberty News (NASDAQ:SCLN)
libertynewsrecord.com - December 13 at 8:15 AM
insidermonkey.com logoIs Actua Corp (ACTA) a Good Stock to Buy? (NASDAQ:SCLN)
www.insidermonkey.com - December 13 at 8:15 AM
News IconStock in Focus: SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) - The Business Journal (NASDAQ:SCLN)
belmontbusinessjournal.com - December 9 at 1:12 AM
News IconNumbers in View on Shares of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) - Liberty News (NASDAQ:SCLN)
libertynewsrecord.com - December 8 at 8:35 AM
News IconStock Tracker: Looking at the Numbers for SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) - The Business Journal (NASDAQ:SCLN)
belmontbusinessjournal.com - December 7 at 12:24 AM
News IconInvestor Watch: Narrowing in on SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) - OIB News (NASDAQ:SCLN)
oibnews.com - December 7 at 12:24 AM
News IconIndicator Review on Shares of SciClone Pharmaceuticals Inc. (SCLN) - StockTalk Daily (NASDAQ:SCLN)
stocktalkdaily.com - December 4 at 6:41 PM
News IconChecking the Numbers on SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) - The Business Journal (NASDAQ:SCLN)
belmontbusinessjournal.com - December 3 at 6:44 PM
News IconMarket Survey: Checking on Shares of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) - OIB News (NASDAQ:SCLN)
oibnews.com - December 2 at 7:21 PM
News IconInvestors are Keeping Tabs on SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) - Marion Business Daily (NASDAQ:SCLN)
marionbusinessdaily.com - December 2 at 7:21 PM
insidermonkey.com logoDo Hedge Funds Love Rent-A-Center Inc (RCII)? (NASDAQ:SCLN)
www.insidermonkey.com - December 2 at 11:42 AM
News IconFree Cash Flow Score in Focus for SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) - The Business Journal (NASDAQ:SCLN)
belmontbusinessjournal.com - November 30 at 7:58 PM
News IconMF Rank in Focus for SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) - OIB News (NASDAQ:SCLN)
oibnews.com - November 30 at 7:58 PM
finance.yahoo.com logoCoverage initiated on SciClone Pharma by Maxim Group (NASDAQ:SCLN)
finance.yahoo.com - November 29 at 3:16 PM
finance.yahoo.com logoCoverage initiated on SciClone Pharma by Maxim Group (NASDAQ:SCLN)
finance.yahoo.com - November 29 at 3:16 PM
News IconStock Watch for SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) - The Business Journal (NASDAQ:SCLN)
belmontbusinessjournal.com - November 28 at 3:51 PM
News IconStock Watch on Shares of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) - OIB News (NASDAQ:SCLN)
oibnews.com - November 28 at 3:51 PM
News IconTechnical Buzz on SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) - The Business Journal (NASDAQ:SCLN)
belmontbusinessjournal.com - November 26 at 2:20 PM
News IconNotable Insider Report: Friedhelm Blobel the President & CEO of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN ... - Thorold News (NASDAQ:SCLN)
www.whatsonthorold.com - November 25 at 7:12 PM
News IconAverage Directional Index in Review for SciClone Pharmaceuticals Inc. (SCLN) - StockTalk Daily (NASDAQ:SCLN)
stocktalkdaily.com - November 23 at 7:37 PM
News IconInvestor Watchlist: Narrowing in on Shares of SciClone Pharmaceuticals Inc. (SCLN) - StockTalk Daily (NASDAQ:SCLN)
stocktalkdaily.com - November 21 at 12:47 PM

Social

What is SciClone Pharmaceuticals' stock symbol?

SciClone Pharmaceuticals trades on the NASDAQ under the ticker symbol "SCLN."

Where is SciClone Pharmaceuticals' stock going? Where will SciClone Pharmaceuticals' stock price be in 2017?

1 analysts have issued 1-year target prices for SciClone Pharmaceuticals' stock. Their predictions range from $14.00 to $14.00. On average, they anticipate SciClone Pharmaceuticals' share price to reach $14.00 in the next twelve months.

When will SciClone Pharmaceuticals announce their earnings?

SciClone Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.

Who owns SciClone Pharmaceuticals stock?

SciClone Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Dimensional Fund Advisors LP (5.66%), Renaissance Technologies LLC (3.47%), State Street Corp (2.81%), Stonepine Capital Management LLC (2.45%), Numeric Investors LLC (1.83%) and AQR Capital Management LLC (1.64%). Company insiders that own SciClone Pharmaceuticals stock include Chuncai Meng, Friedhelm Blobel, Hong Zhao, Lan Xie, Nancy T Chang, Richard J Hawkins and Wilson Wai-Shun Cheung.

Who sold SciClone Pharmaceuticals stock? Who is selling SciClone Pharmaceuticals stock?

SciClone Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Numeric Investors LLC, Oxford Asset Management, Marshall Wace LLP, AQR Capital Management LLC, State Street Corp, Dynamic Technology Lab Private Ltd, Two Sigma Investments LP and Menta Capital LLC. Company insiders that have sold SciClone Pharmaceuticals stock in the last year include Friedhelm Blobel, Nancy T Chang and Wilson Wai-Shun Cheung.

Who bought SciClone Pharmaceuticals stock? Who is buying SciClone Pharmaceuticals stock?

SciClone Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Renaissance Technologies LLC, Guggenheim Capital LLC, Russell Investments Group Ltd., GLG Partners LP, State Board of Administration of Florida Retirement System, Trexquant Investment LP and Bowling Portfolio Management LLC.

How do I buy SciClone Pharmaceuticals stock?

Shares of SciClone Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of SciClone Pharmaceuticals stock cost?

One share of SciClone Pharmaceuticals stock can currently be purchased for approximately $9.65.

SciClone Pharmaceuticals (NASDAQ:SCLN) Chart for Saturday, February, 25, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)

Earnings History Chart

Earnings by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)

Dividend History Chart

Dividend Payments by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)

Last Updated on 2/25/2017 by MarketBeat.com Staff